Cargando…
Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19
The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001057/ https://www.ncbi.nlm.nih.gov/pubmed/33800528 http://dx.doi.org/10.3390/v13030436 |
_version_ | 1783671140858724352 |
---|---|
author | Biernat, Monika Maria Kolasińska, Anna Kwiatkowski, Jacek Urbaniak-Kujda, Donata Biernat, Paweł Janocha-Litwin, Justyna Szymczyk-Nużka, Małgorzata Bursy, Dawid Kalicińska, Elżbieta Simon, Krzysztof Mazur, Grzegorz Wróbel, Tomasz |
author_facet | Biernat, Monika Maria Kolasińska, Anna Kwiatkowski, Jacek Urbaniak-Kujda, Donata Biernat, Paweł Janocha-Litwin, Justyna Szymczyk-Nużka, Małgorzata Bursy, Dawid Kalicińska, Elżbieta Simon, Krzysztof Mazur, Grzegorz Wróbel, Tomasz |
author_sort | Biernat, Monika Maria |
collection | PubMed |
description | The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48–72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma–treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies. |
format | Online Article Text |
id | pubmed-8001057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80010572021-03-28 Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 Biernat, Monika Maria Kolasińska, Anna Kwiatkowski, Jacek Urbaniak-Kujda, Donata Biernat, Paweł Janocha-Litwin, Justyna Szymczyk-Nużka, Małgorzata Bursy, Dawid Kalicińska, Elżbieta Simon, Krzysztof Mazur, Grzegorz Wróbel, Tomasz Viruses Brief Report The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48–72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma–treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies. MDPI 2021-03-08 /pmc/articles/PMC8001057/ /pubmed/33800528 http://dx.doi.org/10.3390/v13030436 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Brief Report Biernat, Monika Maria Kolasińska, Anna Kwiatkowski, Jacek Urbaniak-Kujda, Donata Biernat, Paweł Janocha-Litwin, Justyna Szymczyk-Nużka, Małgorzata Bursy, Dawid Kalicińska, Elżbieta Simon, Krzysztof Mazur, Grzegorz Wróbel, Tomasz Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 |
title | Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 |
title_full | Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 |
title_fullStr | Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 |
title_full_unstemmed | Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 |
title_short | Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 |
title_sort | early administration of convalescent plasma improves survival in patients with hematological malignancies and covid-19 |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001057/ https://www.ncbi.nlm.nih.gov/pubmed/33800528 http://dx.doi.org/10.3390/v13030436 |
work_keys_str_mv | AT biernatmonikamaria earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT kolasinskaanna earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT kwiatkowskijacek earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT urbaniakkujdadonata earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT biernatpaweł earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT janochalitwinjustyna earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT szymczyknuzkamałgorzata earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT bursydawid earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT kalicinskaelzbieta earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT simonkrzysztof earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT mazurgrzegorz earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 AT wrobeltomasz earlyadministrationofconvalescentplasmaimprovessurvivalinpatientswithhematologicalmalignanciesandcovid19 |